Displaying 73 - 84 of 114
Immune-Mediated and Cholestatic Diseases
4

Intercept: PBC Through the Years: Time to Move Ahead - ILC 2022

View
Immune-Mediated and Cholestatic Diseases
4

Albireo Pharma: Idiopathic Cholestasis and Targeted Next-Generation Sequencing Panels: A Case-Based Approach - ILC 2022

View
Immune-Mediated and Cholestatic Diseases
4

Albireo Pharma: Idiopathic Cholestasis and Targeted Next-Generation Sequencing Panels: A Case-Based Approach - ILC 2022

View
Immune-Mediated and Cholestatic Diseases
4

Albireo Pharma: Idiopathic Cholestasis and Targeted Next-Generation Sequencing Panels: A Case-Based Approach - ILC 2022

View
Immune-Mediated and Cholestatic Diseases
1

BioMarin: Gene therapy clinical trials for haemophilia: A partnership between haematologists and hepatologists - ILC 2022

View
Immune-Mediated and Cholestatic Diseases
1

Ipsen: Current challenges in Primary Biliary Cholangitis (PBC): Debating the care odyssey - ILC 2022

View
Immune-Mediated and Cholestatic Diseases
6

Intercept: Providing Better Care in PBC – understanding the evolving evidence - ILC 2021

View
Immune-Mediated and Cholestatic Diseases
6

Intercept: Providing Better Care in PBC – understanding the evolving evidence - ILC 2021

View
Immune-Mediated and Cholestatic Diseases
6

Intercept: Providing Better Care in PBC – understanding the evolving evidence - ILC 2021

View
Immune-Mediated and Cholestatic Diseases
6

Intercept: Providing Better Care in PBC – understanding the evolving evidence - ILC 2021

View
Immune-Mediated and Cholestatic Diseases
6

Intercept: Providing Better Care in PBC – understanding the evolving evidence - ILC 2021

View
Immune-Mediated and Cholestatic Diseases
6

Intercept: Providing Better Care in PBC – understanding the evolving evidence - ILC 2021

View
Displaying 73 - 84 of 114